

**[San Jose State University Special AI Lecture Series III -
AI + Biotech & Physical AI]
The Convergence Revolution - AlphaFold 3, AI-Driven
Biotech, Humanoid Robots, and Future of Physical
Intelligence**

Sunghee Yun

Co-Founder & CTO @ Erudio Bio, Inc.

Co-Founder & CEO @ Erudio Bio Korea, Inc.

Leader of Silicon Valley Privacy-Preserving AI Forum (K-PAI)

CGO / Global Managing Partner @ LULUMEDIC

Global Leadership Initiative Fellow @ Salzburg Global Seminar

Visiting Professor & Advisory Professor @ Sogang Univ. & DGIST

About Speaker

- *Co-Founder & CTO @ Erudio Bio, Inc., San Jose & Novato, CA, USA* 2023 ~
- *Co-Founder & CEO @ Erudio Bio Korea, Inc., Korea* 2025 ~
- *Leader of Silicon Valley Privacy-Preserving AI Forum (K-PAI), CA, USA* 2024 ~
- *CGO / Global Managing Partner @ LULUMEDIC, Seoul, Korea* 2025 ~
- *KFAS-Salzburg Global Leadership Fellow @ Salzburg Global Seminar, Austria* 2024 ~
- *Adjunct Professor, EE Department @ Sogang University, Seoul, Korea* 2020 ~
- *Advisory Professor, EECS Department @ DGIST, Korea* 2020 ~
- *AI-Korean Medicine Integration Initiative Task Force Member @ The Association of Korean Medicine, Seoul, Korea* 2025 ~
- *Director of AI Semiconductor @ K-BioX, CA, USA* 2025 ~
- Global Advisory Board Member @ Innovative Future Brain-Inspired Intelligence System Semiconductor of Sogang University, Korea 2020 ~
- Technology Consultant @ Gerson Lehrman Group (GLG), NY, USA 2022 ~
- Chief Business Development Officer @ WeStory.ai, Cupertino, CA, USA 2025 ~
- Advisor @ CryptoLab, Inc., Seoul, Korea 2025 ~

- Co-Founder & CTO / Head of Global R&D / Chief Applied Scientist / Senior Fellow @ Gauss Labs, Inc., Palo Alto, CA, USA 2020 ~ 2023
- Senior Applied Scientist @ Amazon.com, Inc., Vancouver, BC, Canada 2017 ~ 2020
- Principal Engineer @ Software R&D Center, Samsung Electronics 2016 ~ 2017
- Principal Engineer @ Strategic Marketing & Sales, Memory Business 2015 ~ 2016
- Principal Engineer @ DT Team, DRAM Development, Samsung 2012 ~ 2015
- Senior Engineer @ CAE Team, Memory Business, Samsung, Korea 2005 ~ 2012
- PhD - Electrical Engineering @ Stanford University, CA, USA 2001 ~ 2004
- Development Engineer @ Voyan, Santa Clara, CA, USA 2000 ~ 2001
- MS - Electrical Engineering @ Stanford University, CA, USA 1998 ~ 1999
- BS - Electrical & Computer Engineering @ Seoul National University 1994 ~ 1998

Highlight of Career Journey

- BS in Electrical Engineering (EE) @ Seoul National University
- MS & PhD in Electronics Engineering (EE) @ Stanford University
 - *Convex Optimization - Theory, Algorithms & Software*
 - advisor - *Prof. Stephen P. Boyd*
- Principal Engineer @ Samsung Semiconductor, Inc.
 - *AI & Convex Optimization*
 - collaboration with *DRAM/NAND Design/Manufacturing/Test Teams*
- Senior Applied Scientist @ Amazon.com, Inc.
 - *e-Commerce AIs* - anomaly detection, deep RL, and recommender system
 - *Jeff Bezos's project - drove \$200M* in sales via Amazon Mobile Shopping App
- *Co-Founder & CTO / Global R&D Head & Chief Applied Scientist* @ Gauss Labs, Inc.
- *Co-Founder & CTO* @ Erudio Bio, Inc.
- *Co-Founder & CEO* @ Erudio Bio Korea, Inc.


Unpacking AI

- AI and Biotech - 5
 - AI in biology & AlphaFold 3
 - Emerging Trends in Biotech
 - Bio data integration & biotech companies
- AI-powered Humanoid Robots - 25
 - Tesla Optimus
 - Figure AI
 - Impacts and future outlook
- Selected references - 35
- References - 37

AI & Biotech

AI in biology

- AI has been used in biological sciences, and science in general
- AI's ability to process large amounts of raw, unstructured data (*e.g.*, DNA sequence data)
 - reduces time and cost to conduct experiments in biology
 - enables others types of experiments that previously were unattainable
 - contributes to broader field of engineering biology or biotechnology
- AI increases human ability to make direct changes at cellular level and create novel genetic material (*e.g.*, DNA and RNA) to obtain specific functions




Biotech

Biotech

- biotechnology
 - is multidisciplinary field leveraging broad set of sciences and technologies
 - relies on and builds upon advances in other fields such as nanotechnology & robotics, and, increasingly, AI
 - enables researchers to read and write DNA
 - sequencing technologies “read” DNA while gene synthesis technologies take sequence data and “write” DNA turning data into physical material
- 2018 National Defense Strategy & Senior US Defense and Intelligence Officials identified emerging technologies that could have disruptive impact on US national security [[Say21](#)]
 - [AI](#), lethal autonomous weapons, hypersonic weapons, directed energy weapons, [biotechnology](#), quantum technology
- other names for biotechnology are engineering biology, synthetic biology, biological science (when discussed in context of AI)

Biotech - multidisciplinary field


- sciences and technologies enabling biotechnology include (but not limited to)
 - (molecular) biology, genetics, systems biology, synthetic biology, bio-informatics, quantum computing, robotics [DFJ22]




Convergence of AI and biological design

- AI & biological sciences converging [BKP22]
 - each building upon the other's capabilities for new research and development across multiple areas
- Demis Hassabis, CEO & cofounder of DeepMind, said of biology [Toe23]

“... biology can be thought of as information processing system, albeit extraordinarily complex and dynamic one ... just as mathematics turned out to be the right description language for physics, biology may turn out to be *the perfect type of regime for the application of AI!*”
- both AI & biotech rely on and build upon advances in other scientific disciplines and technology fields, such as nanotechnology, robotics, and increasingly big data (*e.g.*, genetic sequence data)
 - each of these fields itself convergence of multiple sciences and technologies
- so *their impacts can combine to create new capabilities*




Multi-source genetic sequence data



- AI, essential to analyzing exponential growth of genetic sequence data
 - “AI will be essential to fully understanding how genetic code interacts with biological processes” - US National Security Commission on Artificial Intelligence (NSCAI)
 - process huge amounts of biological data, *e.g.*, genetic sequence data, coming from different biological sources for understanding complex biological systems
 - sequence data, molecular structure data, image data, time-series, omics data
- *e.g.*, analyze genomic data sets to determine the genetic basis of particular trait and potentially uncover genetic markers linked with that trait

Quality & quantity of biological data

- limiting factor, however, is *quality and quantity* of biological data, *e.g.*, DNA sequences, that AI is trained on
 - *e.g.*, accurate identification of particular species based on DNA requires reference sequences of *sufficient quality* to exist and be available
- databases have varying standards - access, type, and quality of information
- design, management, quality standards, and data protocols for reference databases can affect utility of particular DNA sequence




Rapid growth of biological data

- volume of genetic sequence data grown exponentially as sequencing technology evolved
- more than 1,700 databases incorporating data on genomics, protein sequences, protein structures, plants, metabolic pathways, *etc.*, *e.g.*
 - open-source public database
 - Protein Data Bank, US-funded data center - more than *terabyte of three-dimensional structure data* for biological molecules, *e.g.*, proteins, DNA, RNA
 - proprietary database
 - Gingko Bioworks - more than *2B protein sequences*
 - public research groups
 - Broad Institute - produces roughly *500 terabases of genomic data per month*
- great potential value in aggregate volume of genetic datasets that can be collectively mined to discover and characterize relationships among genes


Volume and sequencing cost of DNA over time

- volume of DNA sequences & DNA sequencing cost
 - data source: National Human Genome Research Institute (NHGRI) [Wet23] & International Nucleotide Sequence Database Collaboration (INSDC)
- *more dramatic than Moore's law!*

sequences in INSDC



DNA sequencing cost






Bio data availability and bias

- US National Security Commission on Artificial Intelligence (NSCAI) recommends
 - US fund and prioritize development of a biobank containing *“wide range of high-quality biological and genetic data sets securely accessible by researchers”*
 - establishment of database of broad range of human, animal, and plant genomes would
 - *enhance and democratize biotechnology innovations*
 - *facilitate new levels of AI-enabled analysis of genetic data*
- bias - availability of genetic data & decisions about selection of genetic data can introduce bias, *e.g.*
 - training AI model on datasets emphasizing or omitting certain genetic traits can affect how information is used and types of applications developed - *potentially privileging or disadvantaging certain populations*
 - access to data and to AI models themselves may impact communities of differing socioeconomic status or other factors unequally

Emerging Trends in Biotech

AlphaFold

- solving 50-year-old protein folding problem, *“one of biology’s grand challenges”*
 - definition - given amino acid sequence, predict how it folds into a 3D structure
 - proteins fold in microseconds, but predicting computationally nearly impossible
- AlphaFold 1 (2018) - DL + physics-based energy functions → AlphaFold 2 (2020)
 - attention-based NN solving protein folding “in principle” → AlphaFold 3 (2024) - diffusion-based DL, drug-protein interactions, protein complexes
- AlphaFold protein structure database
 - >200MM protein structures - nearly every known protein, used by >2MM researchers
- Applications & implications
 - drug discovery - target identification, lead optimization, side effect prediction
 - enzyme engineering, agriculture, environmental, vaccine development




AlphaGo

- [illegible]





Personalized medicine

- *shift from one-size-fits-all approach to tailored treatments*
- based on individual genetic profiles, lifestyles & environments
- AI enables analysis of vast data to predict patient responses to treatments, thus enhancing efficacy and reducing adverse effects
- *e.g.*
 - custom cancer therapies
 - personalized treatment plans for rare diseases
 - precision pharmacogenomics
- companies - Tempus, Foundation Medicine, *etc.*





AI-driven drug discovery





- traditional drug discovery process - time-consuming and costly often taking decades and billions of dollars
- AI streamlines this process by predicting the efficacy and safety of potential compounds with more speed and accuracy
- AI models analyze chemical databases to identify new drug candidates or repurpose existing drugs for new therapeutic uses
- companies - Insilco Medicine, Atomwise.

Synthetic biology

- use AI for gene editing, biomaterial production and synthetic pathways
- combine principles of biology and engineering to design and construct new biological entities
- AI optimizes synthetic biology processes from designing genetic circuits to scaling up production
- company - Ginkgo Bioworks uses AI to design custom microorganisms for applications ranging from pharmaceuticals to industrial chemicals




Regenerative medicine




- AI advances development of stem cell therapies & tissue engineering
- AI algorithms assist in identifying optimal cell types, predicting cell behavior & personalized treatments
- particularly for conditions such as neurodegenerative diseases, heart failure and orthopedic injuries
- company - Organovo leverages AI to potentially improve the efficacy and scalability of regenerative therapies, developing next-generation treatments

Bio data integration

- integration of disparate data sources, including genomic, proteomic & clinical data - one of biggest challenges in biotech & healthcare
- AI delivers meaningful insights *only when* seamless data integration and interoperability realized
- developing platforms facilitating comprehensive, longitudinal patient data analysis - vital enablers of AI in biotech
- company - Flatiron Health working on integrating diverse datasets to provide holistic view of patient health



Biotech companies




- Atomwise - small molecule drug discovery
- Cradle - protein design
- Exscientia - precision medicine
- Iktos - small molecule drug discovery and design
- Insilico Medicine - full-stack drug discovery system
- Schrödinger, Inc. - use physics-based models to find best possible molecule
- Absci Corporation - antibody design, creating new from scratch antibodies, *i.e.*, “de novo antibodies”, and testing them in laboratories

AI-powered Humanoid Robots

Tesla Optimus

Tesla Optimus

- humanoid robot developed by Tesla intended to handle repetitive & dangerous tasks
- objective - *revolutionize automation* & assist in human labor across various industries
- features - *YouTube - Optimus - Gen 2*
 - dimensions - 5'8" tall & 125 lbs
 - capabilities - lifting weights, walking at 5 MPH & performing everyday tasks
 - AI-powered - runs on Tesla's AI leveraging same technology used in self-driving cars
 - power source - 2.3 KWH battery designed for efficient power management
 - launch year - announced by Elon Musk during Tesla AI Day in 2021
 - *price - \$25,000~\$30,000* expected to decrease over time



History of Tesla Optimus

- inception - first conceptualized as extension of Tesla's AI & robotics capabilities
- AI day 2021 - *officially announced by Elon Musk* w/ vision to solve labor shortages & improve productivity
- Sep 2022 - prototype unveiled
- gen 2 introduced in 2023 - improved capabilities
- Jun 2024 w/ more advanced tasks - *towards mass production for commercial applications*







Figure A1

Figure AI robots

- Figure AI
 - founded in 2022 as Silicon Valley startup company by Brett Adcock - serial entrepreneur with successful Archer Aviation & Vetterly
 - vision of enhancing productivity by integrating AI and robotics into both industrial & personal spaces
- Figure 02
 - 5'6" tall, 154 lbs, payload of 44 lbs, 5 hr runtime, 1.2 m/s speed
 - imitation learning
 - capabilities - advanced cognition, STS task, dexterous hands w/ 16 degrees of freedom





History of Figure AI

- 2022 - founded by Brett Adcock - previously co-founded Archer Aviation & Vetterly
- 2022-2023 - early development - stealth mode focusing on developing their own technology
- May 2023 - public announcement - officially announces mission to develop general-purpose humanoid robots - already raised \$70M @ announcement
- Aug 2023 - unveils Figure 01, first prototype w/ basic mobility & manipulation capabilities
- Oct 2023 - series B funding - raised \$675M beyond initial goal of \$500M - Jeff Bezos, Microsoft, OpenAI - valuation of \sim \$2.6B
- late 2023 \sim early 2024 - partnership announcements - refines humanoid robot technology in locomotion, object manipulation & human-robot interaction
- 2024 - significant strides in robot control & decision-making

Impacts & Future


Impacts on industries & markets

- impacts on robotics history
 - competitor benchmark - competes with robotics giants such as Boston dynamics
 - affordability & scale - predict to lead to *lower costs & higher adoption*
- impacts on labor market
 - task automation - replace human labor in *high-risk & repetitive roles*
 - *job displacement vs creation* - new roles in AI, robot maintenance & oversight
- impacts on consumer market - home automation



Future outlook & predictions

- widespread industrial adoption - expected to become common tool in factories by 2030
- market valued @ *\$1.02B in 2021* - expected *CAGR of 62.5%, 63.1% in hardware segment by 2030* - *31.5% revenue increase in 2021* North America - *10,000 humanoid robots* will be shipped worldwide each year by 2027
- AI evolution - continuous learning and AI enhancements will lead to greater efficiency & adaptability
- consumer integration - long-term vision includes personal assistant
- societal impact - could redefine human roles in industries & homes *raising philosophical & ethical questions on human-robot collaboration*



Selected References & Sources

Selected references & sources

- Robert H. Kane “Quest for Meaning: Values, Ethics, and the Modern Experience” 2013
- Michael J. Sandel “Justice: What’s the Right Thing to Do?” 2009
- Daniel Kahneman “Thinking, Fast and Slow” 2011
- Yuval Noah Harari “Sapiens: A Brief History of Humankind” 2014
- M. Shanahan “Talking About Large Language Models” 2022
- A.Y. Halevry, P. Norvig, and F. Pereira “Unreasonable Effectiveness of Data” 2009
- A. Vaswani, et al. “Attention is all you need” @ NeurIPS 2017
- S. Yin, et. al. “A Survey on Multimodal LLMs” 2023
- Chris Miller “Chip War: The Fight for the World’s Most Critical Technology” 2022
- CEOs, CTOs, CFOs, COOs, CMOs & CCOs @ startup companies in Silicon Valley
- VCs on Sand Hill Road - Palo Alto, Menlo Park, Woodside in California, USA

References

References

- [BKP22] Abhaya Bhardwaj, Shristi Kishore, and Dhananjay K. Pandey. Artificial intelligence in biological sciences. *Life*, 12(1430), 2022.
- [DFJ22] Thomas A. Dixon, Paul S. Freemont, and Richard A. Johnson. A global forum on synthetic biology: The need for international engagement. *Nature Communications*, 13(3516), 2022.
- [HM24] Guadalupe Hayes-Mota. Emerging trends in AI in biotech. *Forbes*, June 2024.
- [Kui23] Todd Kuiken. Artificial intelligence in the biological sciences: Uses, safety, security, and oversight. *Congressional Research Service*, Nov 2023.
- [Say21] Kelley M. Sayler. Defense primer: Emerging technologies. *Congressional Research Service*, 2021.
- [Toe23] Rob Toews. The next frontier for large language models is biology. *Forbes*, July 2023.
- [Wet23] Kris A. Wetterstrand. Dna sequencing costs: Data, 2023.

Thank You